|Toxiciy Grade:||4||City/State/Province:||New York, NY|
|Treatments:||Chemotherapy, Hormone, Biologic therapy||Hospital:||Weill Cornell Medical College|
This phase 2 study involved 11 mantle cell lymphoma patients who had not been previously treated. The median patient age was 60 years and 8 were men.
Patients were treated with the biologic therapy agent bevacizumab and a treatment regimen called R-CHOP that consists of rituximab (biologic) cyclophosphamide, adriamycin, vincristine (chemotherapy), and prednisone (hormone).
The most severe toxicities were of grade 4 and included grade 3-4 anemia, neutropenia, and heart dysfunction.
The median overall survival was 48 months.
One of the authors has received funding from Genentech and Biogen Idec.
Correspondence: Dr. John P. Leonard; email: email@example.com